Abstracts Online:
Search for and view abstracts online by clicking here.
Notifications:
The regular abstract submission site is closed and notifications were sent on May 24, 2012.
The late-breaking abstract site is also closed and notifications were sent in late July.
If you have questions please contact Cristin Watson.
General Information:
- Abstracts must be received by Thursday, April 5, 2012, at 11:59 p.m. Eastern time. Abstracts received after the deadline will not be eligible.
- Abstracts must be submitted online through the abstract submission site. No fax copies, disks or email submissions will be accepted.
- An abstract may only be submitted to the Chicago Multidisciplinary Symposium in Thoracic Oncology once. Duplicate abstracts (reporting the same data) that are submitted under a different author will not be considered.
- Summaries of new, ongoing and updated research in the areas of thoracic oncology will be acceptable for submission and presentation.
- ASTRO will exercise all rights in making sure that abstracts reporting the discovery of scientific research remain in compliance with ACCME standards for offering CME.
- Once an abstract has been selected for presentation it may not be revised. Please proof your abstracts carefully for formatting, spelling and grammar. Double check all sections of the abstract, i.e., title, authors, disclosures and abstract body. Typographical errors that do not affect the data presented or accidental omissions of co-authors may be updated in your presentation or on your poster.
- Abstracts may be edited up to the deadline date of April 5, 2012, at 11:59 p.m., Eastern time. Abstracts will be considered ineligible for review until they are complete. Draft abstracts will not be considered.
- The maximum character limit that includes the title and body of the abstract is 2,500. Spaces are not counted.
- A maximum of 10 author names may be listed on each abstract. There are no exceptions. Please proof your submission and confirm authors prior to submitting.
- It is the responsibility of the submitting author to obtain disclosure information from all co-authors and to report this information electronically during the abstract submission process.
- You will be notified via email of the disposition of your abstract in mid-May 2012. Acceptance of the abstract by the committee obligates the author to present the paper and pay the meeting registration fee. If circumstances prevent attendance, you must notify ASTRO of your withdrawal and arrange for an alternate presenter, preferably a co-author.
- If you wish to withdraw your abstract, you must submit your request in writing by July 1, 2012, to Cristin Watson at cristinw@astro.org. After July 1, 2012, your abstract will be published in the Journal of Thoracic Oncology.
- Submission of an abstract conveys permission to be printed in the Journal of Thoracic Oncology.
- Abstracts may be submitted from any entity producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients reporting on the discovery of their scientific research. Such presentations will be subject to a rigorous peer review process to ensure the validity of the research review process, results and conclusions. In addition, abstract content is subject to change after review and evaluation so that it is not biased toward any proprietary interests.
- Abstracts containing reports on the discovery of scientific research will be evaluated on the following:
- The content does not contain patient care recommendations.
- The content is at the level of biology, physiology or physics and far from a discussion of products that are prescribed to patients.
- The content is about the discovery process itself and not about treatment or diagnostics.
- The content covers research results so early in the discovery process that there is no product developed yet.
- The target learners are scientists who are also participating in the discovery process.
First Author
- An individual may submit more than one abstract in which he or she is indicated as first author but may only present one abstract. If more than one abstract is selected for presentation it must be assigned to the second, or another listed co-author, for presentation. Sponsorship is not required.
- The submitting author and presenting author of an abstract must NOT have a financial interest with the scientific content in the abstract. If a conflict of interest exists, the abstract must be submitted and presented by a co-author with no relevant financial relationship or any commercial interest.
- If the first author, or presenting author, is employed by a commercial interested as defined by the ACCME, an alternate presenter must be named if the abstract is selected for presentation in an oral abstract session.
- All presenters, including poster presenters, are required to register and attend the meeting.
Presentation at Other Meetings
- Abstracts should contain new material that will not have been presented or published prior to the Chicago Multidisciplinary Symposium in Thoracic Oncology, on September 6, 2012. (Exceptions noted below.) If an abstract reporting the same data has been submitted for consideration at another meeting or for publication and you have not received notification of its acceptance at the time of your abstract submission, you will be required to disclose the information during the abstract submission process.
- An exception applies to abstracts submitted or presented at ASCO, ASTRO, IASLC or The University of Chicago sponsored or co-sponsored meetings. Abstracts submitted to prior ASCO, ASTRO, IASLC or he University of Chicago meetings, including annual conferences, will be considered for acceptance but are encouraged to contain new or updated material.
ASTRO – An abstract submitted for presentation at the 2012 ASTRO Annual Meeting may also be submitted for presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology. If your abstract is to be considered for presentation at the ASTRO Annual Meeting, you are encouraged, but not required, to submit updated data.
ASCO – An abstract submitted for presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology may also be submitted for consideration at the 2012 ASCO Annual Meeting.
IASLC – An abstract submitted for presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology may also be submitted for consideration at IASLC meetings.
The University of Chicago – An abstract submitted for presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology may also be submitted for consideration at The University of Chicago meetings.
- Abstract presenters with papers accepted for presentation at another major medical meeting* or accepted for publication after April 5, 2012, are required to notify ASTRO of the change in status by email to Cristin Watson at cristinw@astro.org by July 1, 2012. ASTRO will not consider previously presented or published works for plenary presentation.
*Major medical meetings include annual meetings of national and international societies with attendance of more than 3,000 participants.
Properly Formatted Abstract
- Abstracts must be properly formatted by being organized into four sections identified by the following bolded headers: Purpose/Objectives, Materials/Methods, Results and Conclusions.
- Describe each section in enough detail that the program committee can evaluate the quality and completeness of the abstract.
- Use product-based and generic names wherever possible.
- An abstract may not contain any illustrations, images, graphs or tables. The abstract must be formatted in only text for publication in the meeting program. Any abstract containing an image, graph or table will not be accepted for peer review. If selected, presenters may expand their abstract to include tables, graphs and images in oral/poster presentation.
- The maximum character limit that includes the title and body of the abstract is 2,500. Spaces are not counted.
- A maximum of 10 author names may be listed on each abstract. There are no exceptions.
Submission Topics
- Abstract submissions should be submitted in the most appropriate category. A list of submission categories is available below and in the online submission module. Please note that the symposium program chair has the authority to re-categorize any abstract.
2012 Abstract Topic Categories:
- Small Cell Lung Cancer
- Early-stage Non-small Cell Lung Cancer
- Locally Advanced Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
- Mesothelioma and Other Thoracic Malignancies
- Novel Therapies/Experimental Therapies
- Diagnosis/Staging
- Supportive Care/Palliation
- Outcomes/Health Services Research
- Prevention/Screening
- Biomarkers
Correspondence
- The submitting author will be notified via the email address provided during submission regarding the disposition of their abstract in mid-May.
Embargo Policy
- All abstracts submitted to the Chicago Multidisciplinary Symposium in Thoracic Oncology will be embargoed until the opening ceremony of the meeting, unless otherwise noted by ASTRO.
Press Program Policy
- All abstracts accepted for presentation at the Chicago Multidisciplinary Symposium in Thoracic Oncology may be highlighted in ASTRO’s media program. All submitters must agree to cooperate in the publicity of their study.
Conflict of Interest Policy
ASTRO is an accredited provider of continuing medical education and adheres to the policies and standards set forth by the Accreditation Council for Continuing Medical Education (ACCME). To ensure its compliance, ASTRO expects that the content and related materials will promote improvements or quality in health care and not a specific proprietary business interest or commercial bias. We employ several strategies to ensure absence of bias:
- Disclosure of financial interests and identification and management of potential conflicts. It is the responsibility of the first author to obtain disclosure information from all co-authors and to report this information electronically during the abstract submission.
- A balanced view of therapeutic options will be given.
- A scientifically rigorous review.
- Use of generic names to contribute to impartiality. If trade names are included in your presentation, trade names for several companies should be used where available.
More Information/Questions
For more information or questions, please contact Cristin Watson.
*You will be redirected to the ASTRO website - members will need to log in to their account prior to submitting an abstract. Nonmembers will be instructed to create an account to submit an abstract.